Natalizumab and fingolimod: Insight into their relative efficacies in clinical practice

Abstract

Get full access to this article

View all access options for this article.

References

Miller

Khan

Sheremata

. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15–23.

Kappos

Radue

O’Connor

. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387–401.

Gorelik

Lerner

Bixler

. Anti-JC virus antibodies: Implications for PML risk stratification. Ann Neurol 2010; 68: 295–303.

Carruthers

Rotstein

Healy

. An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy. Mult Scler 2014;

Olsson

Achiron

Alfredsson

. Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Mult Scler 2013; 19: 1533–1538.

Bogdanovic

Priftakis

Hammarin

. Detection of JC virus in cerebrospinal fluid (CSF) samples from patients with progressive multifocal leukoencephalopathy but not in CSF samples from patients with herpes simplex encephalitis, enteroviral meningitis, or multiple sclerosis. J Clin Microbiol 1998; 36: 1137–1138.

D’Agostino

Jr.

Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265–2281.